Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients

• Published in: Breast (Edinburgh) Vol. 32; pp. 119 - 125
• Main Authors: Liu, Xiao-ran, Shao, Bin, Peng, Jia-xi, Li, Hui-ping, Yang, Yan-lian, Kong, Wei-yao, Song, Guo-hong, Jiang, Han-fang, Liang, Xu, Yan, Ying
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.04.2017
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cell Count - methods; Circulating tumor cells; Disease-Free Survival; Female; Hematology, Oncology and Palliative Medicine; Humans; Metastatic breast cancer; Middle Aged; Nanotechnology; Nanotechnology - methods; Neoplasm Metastasis; Neoplastic Cells, Circulating - pathology; Predictive value; Predictive Value of Tests; Prognosis; Predictive value; Metastatic breast cancer; Circulating tumor cells; Nanotechnology
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2017.01.007

Abstract Enumeration of circulating tumor cells (CTCs) is a promising tool in the management of metastatic breast cancer (MBC). This study investigated the capturing efficiency and prognostic value of our previously reported peptide-based nanomagnetic CTC isolation system (Pep@MNPs). We counted CTCs in blood samples taken at baseline (n = 102) and later at patients' first clinical evaluation after starting firstline chemotherapy (n = 72) in a cohort of women treated for MBC. Their median follow-up was 16.3 months (range: 9.0-31.0 months). The CTC detection rate was 69.6 % for the baseline samples. Patients with ≤2 CTC/2 ml at baseline had longer median progression-free survival (PFS) than did those with >2 CTC/2 ml (17.0 months vs. 8.0 months; P = 0.002). Patients with ≤2 CTC/2 ml both at baseline and first clinical evaluation had longest PFS (18.2 months) among all patient groups (P = 0.004). Particularly, among patients with stable disease (SD; per imaging evaluation) our assay could identify those with longer PFS (P < 0.001). Patients with >2 CTC/2 ml at baseline were also significantly more likely to suffer liver metastasis (P = 0.010). This study confirmed the prognostic value of Pep@MNPs assays for MBC patients who undergo firstline chemotherapy, and offered extra stratification regarding PFS for patients with SD, and a possible indicator for patients at risk for liver metastasis.